No insider purchase over the last 90 days. The latest, by 정현호, was filed 03 Aug 2026.
Medy-Tox Inc.: what insiders have been doing
Medy-Tox Inc. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Over the twelve months to 2 November 2026, 14 filings were filed, from 4 insiders.
Both sides are active: 11 purchases worth €345 and 1 sale, from 3 insiders and 1 insider respectively. No amount is published for 11 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 정진향 filed the largest purchase, €345, on 20 April 2026, which represents 0.0001% of the company's market value. On the buying side, the filings list 2 board members, 1 major shareholder and 1 chief executive among the declarants.
The clock since the last published purchase (3 August 2026) now reads 99 days. Filings reach the DART (FSS) feed a median of 6 days after the trade. This delay matters because a trade only becomes useful information once it is public.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 14 filings, this issuer sits above that mark. Our records for Medy-Tox Inc. go back to 2021, with 44 purchases and 3 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -12.5%Entry ₩73,000 · Close 30 Oct 2026 ₩63,900
- -38.6%Entry ₩104,000 · Close 30 Oct 2026 ₩63,900
- -35.6%Entry ₩99,200 · Close 30 Oct 2026 ₩63,900
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 3,465 sharesShareKRXDART:20260803000129Canonical exit: 1 Nov 2026 (T+90)
- 1,450 sharesShareKRXDART:20260730000085Canonical exit: 28 Oct 2026 (T+90)
- 1,254 sharesShareKRXDART:20260707000042Canonical exit: 5 Oct 2026 (T+90)
- 1,315 sharesShareKRXDART:20260626000148Canonical exit: 24 Sept 2026 (T+90)
- 1,315 sharesKRXDART:20260626000178Canonical exit: 24 Sept 2026 (T+90)
- 0KRXDART:20260428000428
- 40 shares@ ₩117,300.000.0001% mcap100.0% of flowShareKRXDART:20260420000490Canonical exit: 1 Jun 2026 (T+90)
- 7,342 sharesKRXDART:20260402000831Canonical exit: 28 Jun 2026 (T+90)
- 7,342 sharesShareKRXDART:20260402000641Canonical exit: 25 Jun 2026 (T+90)
- 100 sharesKRXDART:20260304000181Canonical exit: 25 May 2026 (T+90)
- 330,406 sharesKRXDART:20260303003121
- ●Executives0DART
- 10,792 sharesKRXDART:20251105000048Canonical exit: 28 Jan 2026 (T+90)
- 2,500 sharesShareKRXDART:20251105000039Canonical exit: 3 Feb 2026 (T+90)
- 85,610 sharesKRXDART:20251001000517
- 1,654 sharesShareKRXDART:20250826000071Canonical exit: 24 Nov 2025 (T+90)
- 393,225 sharesKRXDART:20250702000088Canonical exit: 14 Aug 2025 (T+90)
- 1,400 sharesShareKRXDART:20250409000374Canonical exit: 8 Jul 2025 (T+90)
- ShareKRXDART:20240819000193
- ShareKRXDART:20240813000300Canonical exit: 11 Nov 2024 (T+90)
- ShareKRXDART:20240806000174Canonical exit: 31 Oct 2024 (T+90)
- ShareKRXDART:20240626000487Canonical exit: 24 Sept 2024 (T+90)
- 1,464 shares@ ₩136,574.35792.1% of flowShareKRXDART:20240412000415Canonical exit: 10 Jul 2024 (T+90)
25 of 88 declarations
About Medy-Tox Inc.
Medytox is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development of biopharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
